Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide - an international collaborative study - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Haematologica Year : 2020

Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide - an international collaborative study

1 DKFZ - German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg]
2 Heidelberg University Hospital [Heidelberg]
3 CHU Amiens-Picardie
4 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
5 TUM - Technische Universität Munchen - Technical University Munich - Université Technique de Munich
6 University Hospital Carl Gustav Carus [Dresden, Germany]
7 Hôpital JeanMinjoz
8 Klinikum Nürnberg Nord
9 Hôtel-Dieu de Nantes
10 CHRU Montpellier - Hôpital Saint Eloi
11 AP-HP - Hopital Saint-Louis [AP-HP]
12 UPD7 - Université Paris Diderot - Paris 7
13 University Hospital Erlangen = Uniklinikum Erlangen
14 Robert Bosch Gmbh [Schwieberdingen]
15 CHV - Centre Hospitalier de Versailles André Mignot
16 AöR - University Hospital Essen
17 Hôpital Claude Huriez [Lille]
18 KB - Klinikum Bielefeld [Bielefeld, Germany]
19 UKA - Universitätsklinikum RWTH Aachen - University Hospital Aachen [Aachen, Germany]
20 CHR Metz-Thionville - Centre hospitalier régional Metz-Thionville
21 Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]
22 CRCINA-ÉQUIPE 7 - Innate Immunity and Immunotherapy
23 CHU Angers - Centre Hospitalier Universitaire d'Angers
24 FHU GOAL - Fédérations hospitalo-universitaires Grand Ouest Acute Leukemia [Angers]
25 Hôpital Avicenne [AP-HP]
26 UPCité - Université Paris Cité
27 IPC - Institut Paoli-Calmettes
28 CHRO - Centre Hospitalier Régional d'Orléans
29 University Hospital of Würzburg
30 Hôpital Provo
31 VKN - Vivantes Klinikum Neukölln [Berlin, Germany]
32 Gemeinschaftsklinikum Mittelrhein gGmbH [Koblenz, Germany]
33 CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy
34 Ortenau Klinikum Offenburg-Kehl [Offenburg, Germany]
35 Hôpital Dupuytren [CHU Limoges]
36 Centre Hospitalier Victor Dupouy
37 CH Sud Francilien - Centre Hospitalier Sud Francilien [Corbeil-Essonnes]
38 Universität Heidelberg [Heidelberg] = Heidelberg University
39 University Hospital Regensburg
40 St Vincentius Hospital
41 IGR - Institut Gustave Roussy
42 Dynamo - Dynamique moléculaire de la transformation hématopoïétique
43 LMU - Ludwig Maximilian University [Munich] = Ludwig Maximilians Universität München
44 UniversitätsKlinikum Heidelberg
45 TU Dresden - Technische Universität Dresden = Dresden University of Technology
46 Universitätsklinikum Frankfurt am Main [Germany]
47 CAU - Christian-Albrechts-Universität zu Kiel = Christian-Albrechts University of Kiel = Université Christian-Albrechts de Kiel
48 Universität Mannheim
49 University Hospital Leipzig = Universitätsklinikum Leipzig
Delphine Lebon
Ana Berceanu
  • Function : Author
Pierre Peterlin
Yosr Hicheri
  • Function : Author
Celine Berthon
Mathieu Wemeau
  • Function : Author

Abstract

The aim of this study was to characterize a large series of 154 patients with acute promyelocytic leukemia (APL; median age, 53 years; range, 18-90 years) and evaluate real-life outcome after up-front treatment with arsenic trioxide (ATO) and alltrans retinoic acid (ATRA). All patients were included in the prospective NAPOLEON registry (NCT02192619) between 2013 and 2019. APL was de novo in 91% (n=140) and therapy-related in 9% (n=14); 13% (n=20) were older than 70 years. At diagnosis bleeding/hemorrhage was present in 38% and thrombosis in 3%. Complete remission was achieved in 152 patients (99%), whereas two patients (1%) experienced induction death within 18 days after start of therapy. With a median follow-up of 1.99 years (95%-CI, 1.61-2.30 years) 1-year and 2-years overall survival (OS) rates were 97% (95%-CI, 94-100%) and 95% (95%-CI, 91-99%), respectively. Age above 70 years was associated with a significantly shorter OS (P<0.001) as compared to younger patients. So far no relapses were observed. Six patients (4%) died in CR after in median 0.95 years after diagnosis (range, 0.18-2.38 years). Our data confirm the efficiency and durability of ATO/ATRA in the primary management of adult low-/ intermediate-risk APL patients in the real life setting, irrespective of age.

Domains

Cancer
Fichier principal
Vignette du fichier
10285-Article Text-75588-2-10-20211126.pdf (1.89 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

inserm-03540438 , version 1 (24-01-2022)

Identifiers

Cite

Sabine Kayser, Richard Schlenk, Delphine Lebon, Martin Carre, Katharina Götze, et al.. Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide - an international collaborative study. Haematologica, 2020, 106 (12), pp.3100-3106. ⟨10.3324/haematol.2021.278722⟩. ⟨inserm-03540438⟩
36 View
64 Download

Altmetric

Share

Gmail Facebook X LinkedIn More